Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 736 participants.
Also called NCT02058160
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 736 participants
- Sponsor
- Registry
-
NCT02058160 -
2013-003132-79
-
- Other papers using this trial's data
- Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial
- Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Chile, Czechia, Denmark, Estonia, Hungary, Lithuania, Mexico, Netherlands, Poland, Romania, Russia, Slovakia, Spain, Sweden, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT02058160. Randomized; no masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-07 (actual). Results posted on 2017-02-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
- Acronym
- LixiLan-L
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Insulin glargine/lixisenatide (HOE901/AVE0010)
- Intervention (Drug)
- Insulin glargine (HOE901)
- Intervention (Drug)
- Metformin (Background Drug)
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02058160- Content hash
acb0e452c9d8168e6b15e5f5707781f85c560c44c633b386dc25d90849f1e087